• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Introduction to 3-Benzyl-6-chloropyridazine (CAS No. 60906-59-4)

The compound 3-Benzyl-6-chloropyridazine (CAS No. 60906-59-4) is a synthetic organic molecule that belongs to the class of pyridazine derivatives. Pyridazines are six-membered heterocyclic compounds characterized by two nitrogen atoms at positions 1 and 2, which makes them structurally similar to pyridine but with an additional ring substitution. This compound has gained significant attention in recent years due to its potential applications in pharmaceutical research and drug discovery.

3-Benzyl-6-chloropyridazine features a chlorine atom at position 6 and a benzyl group attached at position 3 of the pyridazine ring. The benzyl group, which is an aromatic substituent with a methyl group, contributes to the compound's structural diversity and chemical reactivity. This specific substitution pattern renders the molecule highly suitable for exploring its pharmacological properties and interactions with biological systems.

Recent studies have highlighted the importance of pyridazine derivatives in anticancer drug development. The presence of the chlorine atom at position 6 introduces a degree of electronic variation, which can influence the compound's ability to interact with cellular targets such as enzymes, receptors, and nucleic acids. Additionally, the benzyl group enhances the molecule's lipophilicity, potentially improving its bioavailability and pharmacokinetic profile.

One of the key areas of research involving 3-Benzyl-6-chloropyridazine is its role in inhibiting kinases, particularly in cancer cells. Kinase inhibitors are a cornerstone of modern oncology, as they can block the activity of enzymes critical for cell proliferation and survival. Preclinical studies have demonstrated that this compound exhibits potent inhibitory effects on specific kinase isoforms, making it a promising candidate for further investigation in solid tumor models.

Another significant aspect of 3-Benzyl-6-chloropyridazine is its potential as a template molecule for the development of more complex drugs. Its modular structure allows for easy introduction of additional functional groups, enabling researchers to explore variations that could enhance its therapeutic index or reduce off-target effects. For instance, modifying the benzyl group with electron-donating or withdrawing substituents can fine-tune the compound's pharmacological properties.

Recent advancements in crystallography and structural biology have provided valuable insights into how 3-Benzyl-6-chloropyridazine interacts with its target proteins. High-resolution X-ray crystallography studies have revealed key structural motifs that facilitate binding, which can guide medicinal chemists in optimizing the compound's design for improved efficacy.

Furthermore, computational modeling techniques such as molecular docking and machine learning have been employed to predict the compound's interactions with various drug targets. These predictive methods complement experimental data and accelerate the discovery process by identifying promising candidates early in the research pipeline.

In summary, 3-Benzyl-6-chloropyridazine (CAS No. 60906-59-4) is a versatile and valuable compound in the field of biomedical research. Its unique combination of structural features and pharmacological properties positions it as a strong candidate for further exploration in drug development, particularly in the areas of oncology and kinase inhibition. Ongoing studies aim to elucidate its full potential as a therapeutic agent, paving the way for innovative treatments in disease management.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)